Table 3.
Characteristics of patients with and without hepatitis B virus (HBV) reactivation after withdrawal of lamivudine
| Characteristic | Patients with HBV reactivation after withdrawal of lamivudine (n = 11) | Patients without HBV reactivation after withdrawal of lamivudine (n = 35) | p Value |
| Sex (M:F) | 7:4 | 16:19 | 0.491 |
| Age (y) | 51 (24–71) | 44 (21–78) | 0.787 |
| ALT (U/l) | 21 (12–55) | 28 (10–108) | 0.523 |
| Elevated ALT | 1.000 | ||
| Yes | 1 | 3 | |
| No | 10 | 32 | |
| HBV DNA ⩾104 copies/ml | 0.004 | ||
| Yes | 8 | 8 | |
| No | 3 | 27 | |
| HBeAg | 0.055 | ||
| Positive | 5 | 6 | |
| Negative | 6 | 29 | |
| Diagnosis | 0.689 | ||
| Non-Hodgkin’s lymphoma | 8 | 25 | |
| Hodgkin’s lymphoma | 1 | 1 | |
| Acute myeloid leukaemia | 1 | 7 | |
| Multiple myeloma | 1 | 2 | |
| Duration of lamivudine (months) | 11.8 (7.3–29.3) | 7.8 (7.2–31.5) | 0.634 |
Continuous variables expressed in median (range).
ALT, alanine aminotransaminase (normal range 13–51 U/l).
HBeAg, hepatitis B e antigen.